Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
43%(3 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
2
20%
Ph not_applicable
2
20%
Ph phase_4
1
10%
Ph phase_1
4
40%
Ph phase_3
1
10%

Phase Distribution

4

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(7)
Terminated(2)
Other(1)

Detailed Status

Completed7
Withdrawn1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (40.0%)
Phase 22 (20.0%)
Phase 31 (10.0%)
Phase 41 (10.0%)
N/A2 (20.0%)

Trials by Status

withdrawn110%
terminated110%
completed770%
unknown110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_3

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

NCT03578081
completednot_applicable

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
unknownphase_4

Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia

NCT02953210
completedphase_2

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

NCT00104403
terminatedphase_2

Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

NCT00429702
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03578081Phase 3

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Completed
NCT00343863Not Applicable

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Completed
NCT02953210Phase 4

Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia

Unknown
NCT00104403Phase 2

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

Completed
NCT00429702Phase 2

Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

Terminated
NCT00499668Not Applicable

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Withdrawn
NCT01578265Phase 1

Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fed Condition

Completed
NCT01578252Phase 1

Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting Condition

Completed
NCT01511705Phase 1

Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fasting Condition

Completed
NCT01511718Phase 1

Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fed Condition

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10